Article Text

Download PDFPDF
Multiple sclerosis and risk of cancer: a meta-analysis
  1. Adam E Handel1,2,
  2. Sreeram V Ramagopalan1,2
  1. 1Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
  2. 2Department of Clinical Neurology, University of Oxford, John Radcliffe Hospital, Oxford, UK
  1. Correspondence to Dr Sreeram V Ramagopalan, The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK; sreeramr{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the study by Fois and colleagues, showing no change in the risk of cancer in multiple sclerosis (MS) patients compared with the normal population.1 However, we note that a previous study published this year suggested that MS patients are at lower risk of cancer than the normal population.2 Resolving this controversy is of huge importance for patients and perhaps also for assessing potential adverse effects of immunomodulatory therapies for MS.3

These recent reports, utilising powerful population-based registries, have both shown a decreased risk for all cancers in MS patients, with statistical significance achieved in one study2 but not in …

View Full Text


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.